PAXIL

LOE Approaching

paroxetine hydrochloride

NDAORALTABLET
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
18

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of PAXIL in the treatment of MDD, SAD, OCD, PD, GAD, and PTSD is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin…

Indications (1)

Clinical Trials (5)

NCT04311463Phase 1Completed

Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants

Started Dec 2020
38 enrolled
Anxiety Disorders
NCT01376271N/ACompleted

Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

Started Jan 2010
600 enrolled
Social Phobia
NCT01339247Phase 1Completed

Paxil CR Bioequivalence Study Brazil - Fed Administration

Started Oct 2009
60 enrolled
Depressive Disorder
NCT01316926Phase 1Completed

Paxil CR Bioequivalence Study Brazil

Started Sep 2009
60 enrolled
Depressive Disorder
NCT00812812Phase 4Terminated

Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)

Started Mar 2009
56 enrolled
Depressive Disorder